-
Product Insights
New![]()
Net Present Value Model: Bristol-Myers Squibb Co’s CC-99677
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Bristol-Myers Squibb Co’s CC-90001
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Ranquil Co Norte (Ccs) Field, Argentina
Ranquil Co Norte (Ccs) upstream field is located in Neuquen Province, Argentina. The upstream field is owned by Oilstone Energia SA. It is operated by Oilstone Energia SA. The project started its operations in 2009. Ranquil Co Norte (Ccs) Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-90001 in Sarcomas
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-90001 in Sarcomas Drug Details: CC-90001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-95775 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CC-95775 in Solid Tumor Drug Details: CC-95775 (FT-1101) is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-97540 in Follicular Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CC-97540 in Follicular Lymphoma Drug Details: CC-97540 is under development for the treatment of relapse...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-99282 in Follicular Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-99282 in Follicular Lymphoma Drug Details: CC-99282 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-91633 in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CC-91633 in Myelodysplastic Syndrome Drug Details:CC-91633 (BMS-986397) is under development for the treatment of relapsed or refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-115 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CC-115 in Solid Tumor Drug Details:CC-115 is under development for the treatment of advanced solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-90002 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CC-90002 in Solid Tumor Drug Details:CC-90002 is under development for the treatment of the refractory solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-90001 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-90001 in Solid Tumor Drug Details: CC-90001 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-95775 in Non-Hodgkin Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CC-95775 in Non-Hodgkin Lymphoma Drug Details: CC-95775 (FT-1101) is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-95266 in Refractory Multiple Myeloma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CC-95266 in Refractory Multiple Myeloma Drug Details: CC-95266 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-99282 in Non-Hodgkin Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-99282 in Non-Hodgkin Lymphoma Drug Details: CC-99282 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-99282 in Mantle Cell Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-99282 in Mantle Cell Lymphoma Drug Details: CC-99282 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-90001 in Metastatic Pancreatic Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-90001 in Metastatic Pancreatic Cancer Drug Details: CC-90001 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-90002 in Non-Hodgkin Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CC-90002 in Non-Hodgkin Lymphoma Drug Details:CC-90002 is under development for the treatment of the refractory solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-90001 in Metastatic Colorectal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-90001 in Metastatic Colorectal Cancer Drug Details: CC-90001 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-90002 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CC-90002 in Refractory Multiple Myeloma Drug Details:CC-90002 is under development for the treatment of the refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-90002 in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CC-90002 in Relapsed Multiple Myeloma Drug Details:CC-90002 is under development for the treatment of the refractory...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.